According to the Zhitong Finance App, Xima Ophthalmology (03309) announced annual results for the year ended December 31, 2023, with revenue of HK$1,924 million, up 11.1% year on year; the company's equity holders should have accounted for the profit of HK$61.98 million during the year, while a loss of HK$21.875 million and profit of HK4.94 cents per share was achieved during the same period in 2022.

According to the announcement, total revenue in 2023 was HK$1,924 million, a slight increase of 11.1% over 2022, due to core medical service revenue (including providing ophthalmology services, provision of dental and other medical services, and sale of vision aids) in 2023, which increased 32.9% from HK$1,434 billion in 2022 to HK$1,905 million, offset in part by a 93.5% decrease in revenue from sales of COVID-19-related medical consumables to HK$19.4 million in 2023.